Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dogwood Therapeutics ( (DWTX) ) has shared an announcement.
On September 29, 2025, Dogwood Therapeutics entered into an exclusive licensing agreement with Serpin Pharma and Rejuvenation Labs, granting Dogwood a royalty-free, global license to develop Serpin Pharma’s SP16, a first-in-class LRP1 agonist for treating chemotherapy-induced peripheral neuropathy. This strategic move aligns with Dogwood’s objective to expand its research pipeline in pain and neuropathy management, potentially enhancing its equity value. The transaction involves issuing shares of common and preferred stock to Serpin and Rejuvenation. The SP16 IV formulation is set for a Phase 1b study funded by the National Cancer Institute, highlighting the significant unmet medical need in cancer-related pain management.
The most recent analyst rating on (DWTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Dogwood Therapeutics stock, see the DWTX Stock Forecast page.
Spark’s Take on DWTX Stock
According to Spark, TipRanks’ AI Analyst, DWTX is a Neutral.
Dogwood Therapeutics’ overall stock score reflects its financial challenges typical of early-stage biotech firms, with no revenue and significant reliance on external financing. However, the recent debt conversion strengthens the balance sheet and boosts investor confidence. Technical indicators suggest neutral momentum, with a speculative valuation.
To see Spark’s full report on DWTX stock, click here.
More about Dogwood Therapeutics
Dogwood Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing new medicines to treat pain and neuropathy. The company’s research pipeline includes a non-opioid analgesic program centered on Halneuron®, a NaV1.7 inhibitor, which has shown significant pain reduction in clinical studies.
Average Trading Volume: 19,649
Technical Sentiment Signal: Sell
Current Market Cap: $10.55M
Learn more about DWTX stock on TipRanks’ Stock Analysis page.